牛磺熊去氧膽酸 TUDCA × 肝臟健康
TUDCA-specific human evidence for liver health is limited to a handful of small, dated trials (1993-2013, n=23-150, all roughly 6 months) in patients with established liver disease (cirrhosis, HCV hepatitis, PBC), and every endpoint is a surrogate biochemical marker (ALT/AST/ALP/GGT) with no demonstration of fibrosis reversal or hard clinical outcomes such as survival or transplant-free survival.
TUDCA-specific human evidence for liver health is limited to a handful of small, dated trials (1993-2013, n=23-150, all roughly 6 months) in patients with established liver disease (cirrhosis, HCV hepatitis, PBC), and every endpoint is a surrogate biochemical marker (ALT/AST/ALP/GGT) with no demonstration of fibrosis reversal or hard clinical outcomes such as survival or transplant-free survival. The evidence is also inconsistent: the only head-to-head PBC trial (PMID 8258267) found the parent drug UDCA superior to TUDCA for GGT and tolerability, and TUDCA failed entirely in neonatal TPN-associated cholestasis. No medical institution (Mayo, Cleveland Clinic, Harvard) and no professional society (AASLD, AGA) endorses the TUDCA supplement for liver health, and NIH ODS/NCCIH has no entry at all. Crucially, none of the trials studied general liver health in healthy adults, which is the dominant consumer use case, and the well-established UDCA prescription-drug evidence base must not be conflated with the far thinner TUDCA-supplement data. The totality therefore supports a Grade C: real but small, surrogate-only, inconsistent, and uncertain evidence that falls well short of the Grade B that Examine's aggregated PBC liver-enzyme outcome alone would suggest.
評分透明度
所有分數由 7 層證據引擎計算，過程公開可查▸查看完整決策路徑（audit trail）
- compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.455
- tier_from_score — 依分數區間映射至 tier letter
- apply_hec_rules — 無高階證據可裁決
- tier_strict_requirement_check — Tier 條件達標，未降階
- detect_disputes — 偵測到 0 個 hard + 1 個 soft dispute
- decide_status — 依 tier + dispute 結果決定 status
牛磺熊去氧膽酸（TUDCA）在台灣 PTT／Dcard／Mobile01 等社群幾乎無實質討論串。搜尋結果以 iHerb 國外品牌商品頁、海外部落格與中國大陸醫療文章為主，找不到鄉民實測心得、迷思辯證或副作用回報。屬冷門海外保健品，本層無在地社群訊號，不杜撰討論。
無共識
- 戒酒或減少飲酒
- 體重管理與代謝風險控制
- 病毒性肝炎疫苗接種與篩檢
查看 ClaimReview 結構化資料 (JSON-LD)
{
"@context": "https://schema.org",
"@type": "ClaimReview",
"url": "https://gpt-dict.com/claim/CLM-COND-liver-health-INT-tudca-001/",
"datePublished": "2026-06-01",
"author": {
"@type": "Organization",
"name": "gpt-dict.com",
"url": "https://gpt-dict.com"
},
"claimReviewed": "牛磺熊去氧膽酸能改善肝臟健康",
"inLanguage": "zh-TW",
"itemReviewed": {
"@type": "Claim",
"appearance": []
},
"reviewRating": {
"@type": "Rating",
"ratingValue": 2,
"bestRating": 5,
"worstRating": 1,
"alternateName": "🟠 C 薄弱證據"
}
}